<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Tinea nigra
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Tinea nigra
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Tinea nigra
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alexandro Bonifaz, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andres Tirado-Sanchez, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ted Rosen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 30, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3833551277">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tinea nigra is a superficial mycosis caused by the dematiaceous, yeast-like fungus
         <em>
          Hortaea werneckii
         </em>
         . The infection usually presents as an asymptomatic, hyperpigmented macule or patch on the palm (
         <a class="graphic graphic_picture graphicRef113574 graphicRef113575 graphicRef113576" href="/z/d/graphic/113574.html" rel="external">
          picture 1A-C
         </a>
         ). Less commonly, tinea nigra occurs on the soles of the feet or other sites (
         <a class="graphic graphic_picture graphicRef113578 graphicRef113580 graphicRef113577" href="/z/d/graphic/113578.html" rel="external">
          picture 2A-C
         </a>
         ). The course of tinea nigra is usually chronic, but the infection resolves rapidly with the appropriate treatment.
        </p>
        <p>
         The clinical features, diagnosis, and treatment of tinea nigra are discussed here. Other cutaneous fungal infections are reviewed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">
          "Dermatophyte (tinea) infections"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/99983.html" rel="external">
          "Tinea capitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4039.html" rel="external">
          "Tinea versicolor (pityriasis versicolor)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4260457832">
         <span class="h1">
          MICROBIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tinea nigra is classified as superficial phaeohyphomycosis, a group of fungal infections caused by dematiaceous (pigmented) fungi.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Hortaea werneckii
          </em>
         </strong>
         –
         <strong>
         </strong>
         The most important causative agent is
         <em>
          H. werneckii
         </em>
         , a fungus previously assigned to the genera
         <em>
          Phaeoannellomyces
         </em>
         and
         <em>
          Exophiala
         </em>
         [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/1,2">
          1,2
         </a>
         ].
         <em>
          H. werneckii
         </em>
         is a pleoanamorphic fungus that grows as a black yeast and can transform into a mold.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <em>
          H. werneckii
         </em>
         is halotolerant and halophilic (survives and thrives in high salt concentrations), osmotolerant, and grows in aqueous media. The fungus readily adapts to hypersaline conditions ranging from 3 to 30 percent sodium chloride [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/1-6">
          1-6
         </a>
         ].
         <em>
          H. werneckii
         </em>
         has been isolated in various environments, including coastal areas (beaches and sand), mangrove plants (
         <em>
          Aegiceras corniculatum
         </em>
         ), desalination plants, and desiccated puddles [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/3,7-9">
          3,7-9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other causative fungi
         </strong>
         –
         <strong>
         </strong>
         Other fungi reported to cause tinea nigra include
         <em>
          Cladosporium castellanii
         </em>
         (also known as
         <em>
          Stenella araguata
         </em>
         ) [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/10,11">
          10,11
         </a>
         ],
         <em>
          Phoma hibernica
         </em>
         [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/12">
          12
         </a>
         ], and
         <em>
          Cladophialophora saturnica
         </em>
         (spp nova) [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/13">
          13
         </a>
         ]. Tinea nigra caused by
         <em>
          Curvularia lunata
         </em>
         , a filamentous fungus found in soil and on dead plants, was described in an immunocompetent three-year-old child [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2326622291">
         <span class="h1">
          EPIDEMIOLOGY AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tinea nigra is a rare disease for which there are few epidemiologic data.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidence
         </strong>
         –
         <strong>
         </strong>
         It is estimated that tinea nigra accounts for less than 1 percent of superficial fungal infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age and sex
         </strong>
         –
         <strong>
         </strong>
         Tinea nigra can occur at any age but is most common in children and young adults. There does not appear to be a sex predilection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Geographic distribution
         </strong>
         –
         <strong>
         </strong>
         Tinea nigra is most common in individuals who visit or reside in tropical and subtropical climates [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/1">
          1
         </a>
         ]. It is likely that most patients become infected in aqueous environments (eg, rivers, lakes, and marine areas).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most reported infections have occurred in Central and South America (Mexico, Panama, Brazil, Colombia, and Venezuela), Asia (Japan, India, Sri Lanka, and Burma), Polynesia, and the African coast [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2,15-19">
          2,15-19
         </a>
         ]. Tinea nigra is rarely diagnosed in Europe; reported infections are generally acquired outside of Europe [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/20,21">
          20,21
         </a>
         ]. Both native and non-native (returning traveler) cases have occurred in the United States. Florida, North Carolina, and South Carolina appear to be the most common states for indigenous infections [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/22-24">
          22-24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of hyperhidrosis
         </strong>
         –
         <strong>
         </strong>
         Palmar or plantar hyperhidrosis is an important predisposing factor for tinea nigra. In one series, 9 of 22 patients (41 percent) with tinea nigra had hyperhidrosis [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2">
          2
         </a>
         ]. The association is probably due to the high salt concentration in sweat, which creates conditions similar to those in the natural niche of the fungus [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/1,23">
          1,23
         </a>
         ]. (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1800257740">
         <span class="h1">
          PATHOGENESIS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acquisition
         </strong>
         –
         <strong>
         </strong>
         Tinea nigra develops after direct contact with the fungus in the environment. It is assumed that the infection is not transmitted from person to person.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Minor skin lesions can contribute to infection, which contributes to the palm as a common site. Plantar infections usually occur in people who have walked barefoot in wet or sandy areas (eg, beaches).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The incubation period is not well defined. In a series of 22 patients, the estimated time to the development of visible lesions based on patient recollection was approximately two to four weeks from inoculation [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sites of infection
         </strong>
         –
         <strong>
         </strong>
         On the skin,
         <em>
          H. werneckii
         </em>
         grows in the form of hyphae and brown spores. The depth of infection is limited to the cornified layer of the epidermis, which is hypertrophied by infection. In rare cases, tinea nigra may occur in association with
         <em>
          H. werneckii
         </em>
         infection at other sites. For example,
         <em>
          H. werneckii
         </em>
         peritonitis was reported in a patient on peritoneal dialysis and with tinea nigra on the palm [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2911489745">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Morphology
         </strong>
         –
         <strong>
         </strong>
         The most common manifestation is a unilateral, hyperpigmented, irregularly shaped but well-circumscribed macule or patch with fine scales on the palm (
         <a class="graphic graphic_picture graphicRef113574 graphicRef113575 graphicRef113576" href="/z/d/graphic/113574.html" rel="external">
          picture 1A-C
         </a>
         ) [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/1,2,15,16,19,20,26">
          1,2,15,16,19,20,26
         </a>
         ]. The color typically ranges from light to dark brown. Erythema is not usually present. Bilateral involvement is rare and may be due to autoinoculation [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2,27">
          2,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Distribution
         </strong>
         –
         <strong>
         </strong>
         Although the palm is affected in approximately 80 percent of patients, tinea nigra occasionally occurs on the fingers or in the interdigital spaces (
         <a class="graphic graphic_picture graphicRef113577" href="/z/d/graphic/113577.html" rel="external">
          picture 2C
         </a>
         ) [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2,18,19">
          2,18,19
         </a>
         ]. Infection on the dorsum of the hand is uncommon. The second most common site is the foot, especially on the soles and, less frequently, in the interdigital spaces (
         <a class="graphic graphic_picture graphicRef113578 graphicRef113580" href="/z/d/graphic/113578.html" rel="external">
          picture 2A-B
         </a>
         ) [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/28">
          28
         </a>
         ]. In a series of 22 patients, the soles of the feet were affected in three patients (14 percent), and the palms were affected in the rest [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2">
          2
         </a>
         ]. The arms, legs, neck, and trunk are less commonly affected [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/1,14,26,29">
          1,14,26,29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms
         </strong>
         –
         <strong>
         </strong>
         Most patients are asymptomatic. Occasionally, patients report pruritus; mild erythema may occur at the site of infection in these patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Course
         </strong>
         –
         <strong>
         </strong>
         Without treatment, the course of tinea nigra tends to be chronic. However, spontaneous regression within two to three months has been reported [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2,29">
          2,29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2590101564">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A strong suspicion of tinea nigra may arise from the physical findings of a newly appeared, brown macule or patch, especially if it is on the palm and occurs in a person who lives in or has visited a tropical or subtropical region.
        </p>
        <p>
         A dermoscopic examination can help to clinically differentiate tinea nigra from melanocytic lesions. A potassium hydroxide (KOH) preparation is usually made to confirm the diagnosis. Culture can also confirm the diagnosis and identify the causative organism.
        </p>
        <p>
         Green fluorescence under Wood's lamp examination has also been reported in a patient with interdigital tinea nigra [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1166831651">
         <span class="h2">
          Dermoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dermoscopy is helpful in differentiating tinea nigra from melanocytic lesions, such as acral nevi and melanoma. (See
         <a class="medical medical_review" href="/z/d/html/16551.html" rel="external">
          "Dermoscopy of pigmented lesions of the palms and soles"
         </a>
         .)
        </p>
        <p>
         Typical dermoscopic findings are brown spicules that do not follow the ridges or furrows of the acral dermatoglyphs (skin lines) (
         <a class="graphic graphic_picture graphicRef113582" href="/z/d/graphic/113582.html" rel="external">
          picture 3
         </a>
         ) [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/1,2,30-36">
          1,2,30-36
         </a>
         ]. However, the occurrence of spicules that follow a parallel ridge pattern has been reported [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/37,38">
          37,38
         </a>
         ].
        </p>
        <p>
         Other findings obtained with super-high magnification dermoscopy include linear shapes with undulated forms corresponding to brown, elongated hyphae and spindle-shaped blastoconidia [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1156953544">
         <span class="h2">
          Potassium hydroxide preparation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A potassium hydroxide (KOH) preparation can confirm a fungal infection. Scrapes of the affected skin are placed on a glass slide with 10% KOH and examined with a microscope.
        </p>
        <p>
         In tinea nigra, microscopic examination reveals numerous light brown, fungal elements consisting of septate, variegate, and branched hyphae (
         <a class="graphic graphic_picture graphicRef113583" href="/z/d/graphic/113583.html" rel="external">
          picture 4
         </a>
         ) [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/1,2,15,16">
          1,2,15,16
         </a>
         ]. Clusters of blastoconidia or chlamydoconidia may also be seen. (See
         <a class="medical medical_review" href="/z/d/html/5562.html" rel="external">
          "Office-based dermatologic diagnostic procedures", section on 'Potassium hydroxide preparation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H246237175">
         <span class="h2">
          Culture
         </span>
         <span class="headingEndMark">
          —
         </span>
         A superficial scraping of the affected skin (similar to scraping for a KOH preparation) usually provides a sufficient sample for culture. Cultures for identification of
         <em>
          H. werneckii
         </em>
         are performed on Sabouraud dextrose agar and Sabouraud dextrose agar plus antibiotic media and incubated at 25 to 28°C (77 to 82.4°F). On average, fungal growth can be observed within five to six days [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2">
          2
         </a>
         ].
        </p>
        <p>
         In the initial yeast-like phase, the fungal colonies are smooth, slimy, and olive green to black; in the subsequent mold phase, the fungus appears as filaments with a wooly or velvety appearance (
         <a class="graphic graphic_picture graphicRef113586" href="/z/d/graphic/113586.html" rel="external">
          picture 5
         </a>
         ). In the yeast-like phase, microscopic examination shows abundant budding cells with annellides and characteristic septae (
         <a class="graphic graphic_picture graphicRef113587" href="/z/d/graphic/113587.html" rel="external">
          picture 6
         </a>
         ). In the mold phase, it shows thick, septate hyphae with conidiophores from which sprout numerous arborescent conidia in blastogenic or acropetal formation [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/1,2,16,20">
          1,2,16,20
         </a>
         ]. Additionally, the cultured fungus can also be identified by a polymerase chain reaction assay [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2,40">
          2,40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H594135748">
         <span class="h2">
          Biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin biopsy is not usually required for diagnosis. Skin biopsies are generally performed when another diagnosis (eg, melanoma) is suspected.
        </p>
        <p>
         Characteristic histologic findings of tinea nigra include (
         <a class="graphic graphic_picture graphicRef113588" href="/z/d/graphic/113588.html" rel="external">
          picture 7
         </a>
         ) [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/1,2,30,41">
          1,2,30,41
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperkeratosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild acanthosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Numerous hyphae and pigmented spores within the stratum corneum
        </p>
        <p>
        </p>
        <p>
         Inflammation is usually absent; occasionally, perivascular mononuclear cell infiltrates are present in the dermis.
        </p>
        <p>
         Electron microscopy is not required for diagnosis but shows small fungal colonies with hyphae and blastoconidia within the epidermis [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H900715347">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Noninfectious conditions
         </strong>
         –
         <strong>
         </strong>
         The differential diagnosis for tinea nigra includes other possible causes of skin (especially acral) pigmentation, such as:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Melanocytic nevi
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lentigines
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Melanoma [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/43,44">
          43,44
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dermatitis neglecta (hyperpigmentation of the skin due to inadequate skin cleansing)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Skin discoloration due to metals in contact with the skin (eg, metal rings)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Palmar lichen planus (
         <a class="graphic graphic_picture graphicRef113606" href="/z/d/graphic/113606.html" rel="external">
          picture 8
         </a>
         ) [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/45">
          45
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Phytophotodermatitis (eg, berloque dermatitis (
         <a class="graphic graphic_picture graphicRef113590" href="/z/d/graphic/113590.html" rel="external">
          picture 9
         </a>
         ))
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fixed drug eruptions (
         <a class="graphic graphic_picture graphicRef113592" href="/z/d/graphic/113592.html" rel="external">
          picture 10
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A potassium hydroxide (KOH) preparation, fungal culture, or skin biopsy can be used to differentiate tinea nigra from these disorders. (See
         <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">
          "Lichen planus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89268.html" rel="external">
          "Acquired hyperpigmentation disorders", section on 'Phytophotodermatitis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15760.html" rel="external">
          "Fixed drug eruption"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other dematiaceous fungal infections
         </strong>
         –
         <strong>
         </strong>
         Atypical clinical and KOH preparation findings should raise the possibility of another fungal infection. Superficial infections with other dematiaceous fungi, such as
         <em>
          Exophiala mansoni
         </em>
         [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/46">
          46
         </a>
         ],
         <em>
          Neoscytalidium dimidiatum
         </em>
         (formerly
         <em>
          Scytalidium
         </em>
         ) [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/47">
          47
         </a>
         ], or
         <em>
          Aureobasidium melanogenum
         </em>
         [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/48">
          48
         </a>
         ], may be associated with cutaneous hyperpigmentation and a positive KOH preparation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For example, a patient with
         <em>
          A. melanogenum
         </em>
         infection presented with hyperpigmented patches on the face that were less well defined than typical tinea nigra and were accompanied by erythematous papules. A KOH preparation showed dark, septate oval cells with thick septae and septate hyphae. [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/48">
          48
         </a>
         ]. In such patients, fungal cultures are useful for definitive diagnosis [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3540069154">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         No randomized trials have been conducted for the treatment of tinea nigra. Efficacy data are limited to case reports and small case series.
        </p>
        <p class="headingAnchor" id="H2162655969">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical therapy is the preferred mode of treatment for tinea nigra. Clinical experience and case reports suggest efficacy of both topical antifungal agents and topical keratolytic agents. Systemic therapy is rarely necessary. (See
         <a class="local">
          'Role of systemic antifungal therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3700485425">
         <span class="h3">
          Topical antifungal and keratolytic agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical antifungal agents and topical keratolytics are the mainstays of therapy. Selection of a topical treatment is generally based on clinician familiarity with specific agents and treatment availability.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical antifungal drugs
         </strong>
         –
         <strong>
         </strong>
         Topical antifungal drugs are the most frequently reported therapies for tinea nigra [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/14">
          14
         </a>
         ]. Benefit of various antifungal drugs, such as imidazoles (eg, bifonazole [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2,49">
          2,49
         </a>
         ],
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/27">
          27
         </a>
         ], isoconazole [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/50,51">
          50,51
         </a>
         ],
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/52">
          52
         </a>
         ],
         <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">
          miconazole
         </a>
         [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/53">
          53
         </a>
         ], and
         <a class="drug drug_general" data-topicid="10187" href="/z/d/drug information/10187.html" rel="external">
          sertaconazole
         </a>
         [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/54">
          54
         </a>
         ]),
         <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">
          terbinafine
         </a>
         [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/50,55">
          50,55
         </a>
         ],
         <a class="drug drug_general" data-topicid="9177" href="/z/d/drug information/9177.html" rel="external">
          butenafine
         </a>
         [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/56">
          56
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9263" href="/z/d/drug information/9263.html" rel="external">
          ciclopirox
         </a>
         [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/57">
          57
         </a>
         ], is documented in case reports or case series. We usually select an imidazole for topical antifungal treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Topical antifungal agents are typically applied twice daily until clinical resolution. Resolution is expected within two to three weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Whitfield ointment
         </strong>
         –
         <strong>
         </strong>
         Whitfield ointment, which contains 3% salicylic acid (a keratolytic agent) and 6% benzoic acid (a drug with antifungal properties), or similar formulations also appear effective for tinea nigra [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2,16">
          2,16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whitfield ointment is typically applied twice daily for two to three weeks. In one series, twice-daily treatment with Whitfield ointment was associated with resolution of tinea nigra in 10 of 11 patients [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2">
          2
         </a>
         ]. The mean treatment duration was 18 days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other keratolytic agents
         </strong>
         –
         <strong>
         </strong>
         Use of other keratolytic agents, such as 3% salicylic acid alone or urea-containing agents, has been suggested [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/1,58">
          1,58
         </a>
         ]. However, efficacy data for these therapies are more limited.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3708347256">
         <span class="h3">
          Treatment of hyperhidrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperhidrosis may be a risk factor for recurrence of tinea nigra. In our experience, concurrent treatment of hyperhidrosis (if present) may be required. (See
         <a class="local">
          'Epidemiology and risk factors'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5567.html" rel="external">
          "Primary focal hyperhidrosis", section on 'Palmar or plantar hyperhidrosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3619925629">
         <span class="h2">
          Role of systemic antifungal therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic therapy is not usually indicated. In practice, use of systemic therapy is rare (ie, generally limited to patients with recurrences associated with severe hyperhidrosis or other predisposing factors and patients who are unable to perform topical treatment).
        </p>
        <p>
         In one case report, disappearance of tinea nigra occurred with administration of 200 mg of oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         per day for three weeks [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/59">
          59
         </a>
         ]. In our experience, 100 mg of itraconazole per day for 15 to 30 days has been sufficient in adults with recurrent tinea nigra. In an in vitro study evaluating the sensitivity of
         <em>
          H. werneckii
         </em>
         to nine antifungal agents, itraconazole was one of several drugs with low minimal inhibitory concentrations [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/60">
          60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1085423360">
         <span class="h2">
          Other therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some authors have suggested that other approaches might be effective, such as physical scraping of the lesions with a scalpel or curette [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/16,61">
          16,61
         </a>
         ]. Resolution with topical thiabendazole is documented in a case report [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/62">
          62
         </a>
         ]. In our experience, other topical agents, including 1% iodine tincture and 3% sulfur, can also be effective.
        </p>
        <p class="headingAnchor" id="H3792222434">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tinea nigra generally responds rapidly to topical therapy. If tinea nigra does not respond to topical treatment, the diagnosis and patient adherence to the treatment regimen should be confirmed. (See
         <a class="local">
          'General approach'
         </a>
         above.)
        </p>
        <p>
         Tinea nigra usually does not recur after treatment. However, continued contact with environmental conditions that favor
         <em>
          H. werneckii
         </em>
         is a risk factor for reinfection. (See
         <a class="local">
          'Epidemiology and risk factors'
         </a>
         above.)
        </p>
        <p>
         Occasional spontaneous disappearance of tinea nigra has been reported [
         <a class="abstract_t" href="/contents/tinea-nigra/abstract/2,29">
          2,29
         </a>
         ]. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3063975148">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83426.html" rel="external">
          "Patient education: Tinea nigra (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1571924108">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiology
         </strong>
         –
         <strong>
         </strong>
         Tinea nigra is a rare fungal infection of the skin caused mainly by
         <em>
          Hortaea werneckii
         </em>
         , a dematiaceous (pigmented) fungus.
         <em>
          H. werneckii
         </em>
         grows in aqueous environments and can survive in high salt concentrations. (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology and risk factors
         </strong>
         –
         <strong>
         </strong>
         Tinea nigra typically occurs in individuals (most often children and young adults) who have visited or live in tropical or subtropical climates. Infection occurs through direct contact with the fungus in the environment. It is likely that most patients become infected in water-rich environments, such as river beaches, lakes, and marine areas. Hyperhidrosis is a risk factor for infection. (See
         <a class="local">
          'Epidemiology and risk factors'
         </a>
         above and
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         –
         <strong>
         </strong>
         Tinea nigra usually presents as a unilateral, hyperpigmented, irregularly shaped but well-circumscribed, brown macule or patch with fine scales. The palm is most commonly affected (
         <a class="graphic graphic_picture graphicRef113574 graphicRef113575 graphicRef113576" href="/z/d/graphic/113574.html" rel="external">
          picture 1A-C
         </a>
         ). Less commonly, tinea nigra occurs on the feet, elsewhere on the hand, or in other areas of the body (
         <a class="graphic graphic_picture graphicRef113578 graphicRef113580 graphicRef113577" href="/z/d/graphic/113578.html" rel="external">
          picture 2A-C
         </a>
         ). The infection is usually asymptomatic. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         –
         <strong>
         </strong>
         The diagnosis of tinea nigra is made based upon consistent physical findings and confirmation of fungal infection. A potassium hydroxide (KOH) preparation or fungal culture can be used to confirm fungal infection (
         <a class="graphic graphic_picture graphicRef113583" href="/z/d/graphic/113583.html" rel="external">
          picture 4
         </a>
         ). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         –
         <strong>
         </strong>
         Tinea nigra responds rapidly to appropriate therapy. We suggest treatment with topical, rather than systemic, agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Limited data suggest that topical antifungal agents and topical keratolytic agents are effective treatments. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/1">
           Bonifaz A, Gómez-Daza F, Paredes V, Ponce RM. Tinea versicolor, tinea nigra, white piedra, and black piedra. Clin Dermatol 2010; 28:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/2">
           Bonifaz A, Badali H, de Hoog GS, et al. Tinea nigra by Hortaea werneckii, a report of 22 cases from Mexico. Stud Mycol 2008; 61:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/3">
           Chen J, Xing XK, Zhang LC, et al. Identification of Hortaea werneckii Isolated from mangrove plant Aegiceras comiculatum based on morphology and rDNA sequences. Mycopathologia 2012; 174:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/4">
           de Hoog GS, Gerrits van den Ende AH. Nutritional pattern and eco-physiology of Hortaea werneckii, agent of human tinea nigra. Antonie Van Leeuwenhoek 1992; 62:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/5">
           Petrovic U. Role of oxidative stress in the extremely salt-tolerant yeast Hortaea werneckii. FEMS Yeast Res 2006; 6:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/6">
           Kogej T, Stein M, Volkmann M, et al. Osmotic adaptation of the halophilic fungus Hortaea werneckii: role of osmolytes and melanization. Microbiology 2007; 153:4261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/7">
           Gunde-Cimermana N, Zalarb P, de Hoogc S, Plemenitasd A. Hypersaline waters in salterns - natural ecological niches for halophilic black yeasts. FEMS Microbiol Ecol 2000; 32:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/8">
           Efstratiou MA, Velegraki A. Recovery of melanized yeasts from Eastern Mediterranean beach sand associated with the prevailing geochemical and marine flora patterns. Med Mycol 2010; 48:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/9">
           Zalar P, de Hoog S, Gunde-Cimerman N. Ecology of the halotolerant dothideaceous black yeasts. Stud Mycol 1999; 43:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/10">
           Borelli D, Marcano C. Cladosporium castellani nova species, agente de tinea nigra. Castellania 1973; 1:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/11">
           Crous PW, Braun U, Schubert K, Groenewald JZ. Delimiting Cladosporium from morphologically similar genera. Stud Mycol 2007; 58:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/12">
           Bakerspigel A. The isolation of Phoma hibernica from a lesion on a leg. Sabouraudia 1970; 7:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/13">
           Badali H, Carvalho VO, Vicente V, et al. Cladophialophora saturnica sp. nov., a new opportunistic species of Chaetothyriales revealed using molecular data. Med Mycol 2009; 47:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/14">
           Al-Odaini N, Wei JY, Zheng YQ, et al. A Special Tinea Nigra Caused by Curvularia lunata: Case Report and Literature Review. Mycopathologia 2022; 187:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/15">
           Severo LC, Bassanesi MC, Londero AT. Tinea nigra: report of four cases observed in Rio Grande do Sul (Brazil) and a review of Brazilian literature. Mycopathologia 1994; 126:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/16">
           Perez C, Colella MT, Olaizola C, et al. Tinea nigra: report of twelve cases in Venezuela. Mycopathologia 2005; 160:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/17">
           Cabrera R, Sabatin N, Urrutia M, Sepúlveda R. [Tinea nigra: a allochthonous case report in Chile]. Rev Chilena Infectol 2013; 30:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/18">
           Pegas JR, Criado PR, Lucena SK, de Oliveira MA. Tinea nigra: report of two cases in infants. Pediatr Dermatol 2003; 20:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/19">
           Uezato H, Gushi M, Hagiwara K, et al. A case of tinea nigra palmaris in Okinawa, Japan. J Dermatol 2006; 33:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/20">
           Hughes JR, Moore MK, Pembroke AC. Tinea nigra palmaris. Clin Exp Dermatol 1993; 18:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/21">
           Cabañes FJ, Bragulat MR, Castellá G. Hortaea werneckii isolated from silicone scuba diving equipment in Spain. Med Mycol 2012; 50:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/22">
           Khan A, McIver FA. A case of tinea nigra palmaris from Charleston,, South Carolina. J S C Med Assoc 1980; 76:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/23">
           WATKINS DB. TINEA NIGRA. REPORT OF A CASE IN FLORIDA. Dermatol Trop Ecol Geogr 1964; 30:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/24">
           VANVELSOR H, SINGLETARY H. TINEA NIGRA PALMARIS. A REPORT OF 15 CASES FROM COASTAL NORTH CAROLINA. Arch Dermatol 1964; 90:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/25">
           Chamroensakchai T, Kleebchaiyaphum C, Tatiyanupanwong S, et al. Tinea nigra palmaris-associated peritonitis, caused by Hortaea werneckii: The first case report in a peritoneal dialysis patient. Perit Dial Int 2021; 41:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/26">
           Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra, and piedra. Dermatol Clin 2003; 21:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/27">
           Sarangi G, Dash D, Chayani N, et al. Bilateral Tinea Nigra of palm: a rare case report from Eastern India. Indian J Med Microbiol 2014; 32:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/28">
           Ibraheim MK, McNally MA, Tschen J. Interdigital Tinea Nigra. Cureus 2020; 12:e7579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/29">
           Rossetto AL, Cruz RC. Spontaneous cure in a case of Tinea nigra. An Bras Dermatol 2012; 87:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/30">
           Smith SB, Beals SL, Elston DM, Meffert JJ. Dermoscopy in the diagnosis of tinea nigra plantaris. Cutis 2001; 68:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/31">
           Paschoal FM, de Barros JA, de Barros DP, et al. Study of the dermatoscopic pattern of tinea nigra: report of 6 cases. Skinmed 2010; 8:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/32">
           Piliouras P, Allison S, Rosendahl C, et al. Dermoscopy improves diagnosis of tinea nigra: a study of 50 cases. Australas J Dermatol 2011; 52:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/33">
           Criado PR, Delgado L, Pereira GA. Dermoscopy revealing a case of Tinea Nigra. An Bras Dermatol 2013; 88:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/34">
           Maia Abinader MV, Carvalho Maron SM, Araújo LO, Silva Ado A. Tinea nigra dermoscopy: A useful assessment. J Am Acad Dermatol 2016; 74:e121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/35">
           Xavier MH, Ribeiro LH, Duarte H, et al. Dermatoscopy in the diagnosis of tinea nigra. Dermatol Online J 2008; 14:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/36">
           Thomas CL, Samarasinghe V, Natkunarajah J, Fogo A. Entodermoscopy: a spotlight on tinea nigra. Int J Dermatol 2016; 55:e117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/37">
           Nazzaro G, Ponziani A, Cavicchini S. Tinea nigra: A diagnostic pitfall. J Am Acad Dermatol 2016; 75:e219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/38">
           Noguchi H, Hiruma M, Inoue Y, et al. Tinea nigra showing a parallel ridge pattern on dermoscopy. J Dermatol 2015; 42:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/39">
           Cinotti E, Ekinde S, Labeille B, et al. Image Gallery: Pigmented hyphae can be identified in vivo by high and super-high magnification dermoscopy. Br J Dermatol 2019; 181:e4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/40">
           Abliz P, Fukushima K, Takizawa K, et al. Specific oligonucleotide primers for identification of Hortaea werneckii, a causative agent of tinea nigra. Diagn Microbiol Infect Dis 2003; 46:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/41">
           Hasegawa T, Matsukura T, Mizuno Y, et al. Clinical trial of a laser device called fractional photothermolysis system for acne scars. J Dermatol 2006; 33:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/42">
           Guarenti IM, Almeida HL Jr, Leitão AH, et al. Scanning electron microscopy of tinea nigra. An Bras Dermatol 2014; 89:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/43">
           Tseng SS, Whittier S, Miller SR, Zalar GL. Bilateral tinea nigra plantaris and tinea nigra plantaris mimicking melanoma. Cutis 1999; 64:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/44">
           Hall J, Perry VE. Tinea nigra palmaris: differentiation from malignant melanoma or junctional nevi. Cutis 1998; 62:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/45">
           Madke B, Doshi B, Wankhede P, Nayak C. Palmar lichen planus mimicking tinea nigra. Indian J Dermatol 2013; 58:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/46">
           Listemann H, Sinner U, Meigel W. [Exophiala mansonii as the pathogen in superficial phaeohyphomycosis]. Mykosen 1986; 29:480, 483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/47">
           Machouart M, Menir P, Helenon R, et al. Scytalidium and scytalidiosis: what's new in 2012? J Mycol Med 2013; 23:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/48">
           Chen WT, Tu ME, Sun PL. Superficial Phaeohyphomycosis Caused by Aureobasidium melanogenum Mimicking Tinea Nigra in an Immunocompetent Patient and Review of Published Reports. Mycopathologia 2016; 181:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/49">
           Sayegh-Carreño R, Abramovits-Ackerman W, Girón GP. Therapy of tinea nigra plantaris. Int J Dermatol 1989; 28:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/50">
           Rossetto AL, Cruz RC, Haddad Junior V. Double-blind study with topical Isoconazole and Terbinafine for the treatment of one patient with bilateral Tinea nigra plantaris and suggestions for new differential diagnosis. Rev Inst Med Trop Sao Paulo 2013; 55:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/51">
           Falcão EM, Trope BM, Martins NR, et al. Bilateral Tinea Nigra Plantaris with Good Response to Isoconazole Cream: A Case Report. Case Rep Dermatol 2015; 7:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/52">
           Burke WA. Tinea nigra: treatment with topical ketoconazole. Cutis 1993; 52:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/53">
           Marks JG Jr, King RD, Davis BM. Treatment of tinea nigra palmaris with miconazole. Arch Dermatol 1980; 116:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/54">
           Fierro-Arias L, Echevarría-Keel J, Huesca A, Bonifaz A. Tiña negra palmar tratada con sertaconazol crema (2%). Dermatol Rev Mex 2016; 60:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/55">
           Shannon PL, Ramos-Caro FA, Cosgrove BF, Flowers FP. Treatment of tinea nigra with terbinafine. Cutis 1999; 64:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/56">
           Rossetto AL, Cruz RC. Tinea nigra: successful treatment with topical butenafine. An Bras Dermatol 2012; 87:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/57">
           Rosen T, Lingappan A. Rapid treatment of tinea nigra palmaris with ciclopirox olamine gel, 0.77%. Skinmed 2006; 5:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/58">
           Giordano L MC, De la Fuente L A, Lorca J MB, Kramer H D. Tinea nigra: Report of three pediatrics cases. Rev Chil Pediatr 2018; 89:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/59">
           Gupta G, Burden AD, Shankland GS, et al. Tinea nigra secondary to Exophiala werneckii responding to itraconazole. Br J Dermatol 1997; 137:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/60">
           Badali H, Al-Hatmi AMS, Fakhim H, et al. In vitro activity of nine antifungal agents against a global collection of Hortaea werneckii isolates, the agent of tinea nigra. Int J Antimicrob Agents 2019; 54:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/61">
           Dias MF, Quaresma-Santos MV, Bernardes-Filho F, et al. Update on therapy for superficial mycoses: review article part I. An Bras Dermatol 2013; 88:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t" href="/contents/tinea-nigra/abstract/62">
           Carr JF, Lewis CW. Tinea nigra palmaris. Treatment with thiabendazole topically. Arch Dermatol 1975; 111:904.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 110106 Version 4.0
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
